Form 4: NewAmsterdam Pharma Director Acquires Shares and Options

Director William Lewis of NewAmsterdam Pharma Co N.V. acquired 6,960 restricted stock units and options for 32,500 ordinary shares.

Summary

• William Lewis, a director at NewAmsterdam Pharma Co N.V., has reported changes in his beneficial ownership of the company's securities.
• On January 7, 2025, Mr. Lewis acquired 6,960 restricted stock units (RSUs), each representing a right to receive one ordinary share.
• These RSUs were granted for no consideration and will vest in three equal annual installments starting on the first anniversary of the vesting start date.
• Additionally, on January 6, 2025, Mr. Lewis was granted an option to purchase 32,500 ordinary shares at an exercise price of $25.85 per share.
• The options vest over three years, with one-third vesting on January 6, 2026, and the remainder vesting monthly over the following two years.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of equity grants to a director, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future prospects.
• The vesting schedule of the RSUs and options aligns the director's interests with the long-term performance of the company.

Industry Context

This is a standard SEC Form 4 filing, which is a routine disclosure for company insiders who have made transactions in their company's securities. It is common for directors to receive stock options and restricted stock units as part of their compensation.

Comparison to Industry Standards

• The vesting schedules for the RSUs and options are typical for executive compensation packages in the pharmaceutical industry.
• The exercise price of $25.85 for the options is a standard practice, often set at or near the market price at the time of grant.
• Similar filings can be seen from directors at companies such as Amgen, Regeneron, and Gilead, who also receive equity-based compensation.

Stakeholder Impact

• The acquisition of shares and options by a director can be viewed positively by shareholders as it demonstrates confidence in the company's future.

Key Dates

Keywords

insider trading, Form 4, beneficial ownership, restricted stock units, stock options, equity securities, NewAmsterdam Pharma